INVESTIGATIONAL COMPOUND BREXPIPRAZOLE MET PRIMARY AND SECONDARY STUDY ENDPOINTS IN PHASE III CLINICAL TRIAL IN MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka Holdings announces 3Q FY2013 financial results.
Otsuka announces 2013 fourth quarter U.S. net sales figures of ABILIFY®
Otsuka and Lundbeck to present new data on brexpiprazole in major depressive disorder (MDD) at European Psychiatry Association 2014 Congress
Otsuka Pharmaceutical Submits Marketing Authorization Application in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia